Cargando…
Evolution of the Thrombolytic Treatment Window for Acute Ischemic Stroke
Ischemic stroke is a major cause of morbidity and mortality for which the only approved treatment in the acute setting is intravenous thrombolysis. The efficacy and safety of recombinant tissue plasminogen activator (rt-PA) have been firmly established within 3 h of symptom onset; however, few patie...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Current Science Inc.
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828551/ https://www.ncbi.nlm.nih.gov/pubmed/20425223 http://dx.doi.org/10.1007/s11910-009-0076-8 |